Celgene Stock Price - CELG

Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
After Hours
Last Trade
Last $ 102.89 ▼ -0.06 (-0.06%)
Company Name Stock Ticker Symbol Market Type
Celgene Corporation CELG NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  1.15 1.13% 102.95 103.075 101.69 102.20 101.80 23:59:43
Bid Price Ask Price Spread Spread % News
100.00 104.27 4.27 4.1% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
36,039 4,900,549 $ 102.69 $ 503,214,197 3,565,119 58.59 - 103.075
Last Trade Time Type Quantity Stock Price Currency
18:26:50 50 $ 103.00 USD

Celgene Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 72.96B 708.74M $ 4.05B 5.52 13.40 704.90M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 37.00 0.50%

more financials information »

Celgene News

Loading Messages....

Latest CELG Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CELG Price Data

Period † Open High Low VWAP Avg. Daily Vol [m] Change %
1 Week100.25103.07599.98100.98443M2.72.69%
1 Month98.65103.07597.399.44144M4.34.36%
3 Months92.17103.07591.5596.93403M10.7811.70%
6 Months94.67103.07589.0395.31844M8.288.75%
1 Year84.13103.07558.5986.41447M18.8222.37%
3 Years100.35147.1758.5997.49796M2.62.59%
5 Years88.84147.1758.59102.49845M14.1115.88%

Celgene Description

Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Recent acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline.

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.